Navigation Links
QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2007
Date:1/17/2008

VANCOUVER, Jan. 17 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$45.5 million for the quarter and US$214.9 million for the full year ended December 31, 2007. Visudyne sales for the fourth quarter declined by 40.5% over the same quarter in 2006 and the full year represented a decrease of 39.3% over annual sales in 2006. Visudyne sales in the U.S. for the quarter were approximately US$10 million, representing 22% of total sales for the quarter. U.S. average daily Visudyne sales increased to 127 vials in the fourth quarter of 2007 compared to 118 vials in the third quarter of 2007. The growth in daily Visudyne vial sales translates to a US$0.6 million increase quarter over quarter.

QLT will release its full financial results on Thursday, February 21, 2008, at 7:30 a.m. Eastern Time (ET).

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

Conference call information

QLT Inc. will hold an investor conference call to discuss year end results for 2007 on Thursday, February 21 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet at http://www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7142, followed by the number sign.

A full explanation of how QLT determines and recognizes revenue resulting from Visudyne sales is contained in the financial statements contained in the periodic reports on Forms 10-Q and 10-K, under the heading "Significant Accounting Policies - Revenue Recognition." Visudyne sales are product sales by Novartis under its agreement with QLT.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-Synthelabo Inc.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol

"QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

The Visudyne(R) sales figures in this press release are preliminary and

unaudited and are not a complete disclosure of our annual financial

results.

CONTACT: QLT Inc.: Vancouver, Canada, Tamara Hicks, or Therese Hayes, Telephone: (604) 707-7000, or 1-800-663-5486, Fax: (604) 707-7001


'/>"/>
SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... 24, 2017 , ... Labs often perform the same operations ... operators and management to assess these processes with a critical eye—particularly in the ... , Created with the help of both internal and external process experts, ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each person ... author, Jerri Broglin, a survivor of great loss who gained insight on how to ... those searching for answers, as we are finding the answers that are so deep ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/24/2017)... ... 24, 2017 , ... Anaconda BioMed, a pre-clinical stage medical ... treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna Medical ... towards regulatory and clinical phases. , "This is another important step for Anaconda ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... R.I. , April 20, 2017  CVS ... CVS), today unveiled a new store design to ... assortment of healthier food, health-focused products and expanded ... store to help customers discover new offerings. Together ... the next evolution of the customer experience at ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: